Citable filing context
WST's research view summarizes recent SEC filing context, starting with earnings from Jul 23, 2026.
| Filed | Item | Context |
|---|---|---|
| Jul 23, 2026 | earnings | West Pharmaceutical Services reported Q2 2026 net sales of $872.3 million and raised full-year 2026 EPS guidance. |
| Jul 14, 2026 | material_agreement | West Pharmaceutical Services and Daikyo Seiko entered into a 10-year technology cross-license and distributorship agreement. |
| Jun 1, 2026 | management_change | West Pharmaceutical Services appointed Michel Lagarde as President and CEO, effective August 31, 2026. |
| Jul 23, 2026 | Guidance: adjusted_diluted_eps | 8.85 to 9.05 |
| Jul 23, 2026 | Guidance: adjusted_diluted_eps | 2.14 to 2.24 |
| Jul 23, 2026 | Guidance: net_sales | 820.00 to 835.00 |
| Jul 23, 2026 | mda_quarterly | West Pharmaceutical Services reported strong financial growth for the second quarter of 2026, with consolidated net sales rising 13.8% to $872.3 million. This performance was driven primarily by the Proprietary Products segment, which saw a 16.6% sales increase fueled by robust demand for Biologics and GLP-1 products, alongside higher sales of high-value components and delivery devices. The West Vantage segment (formerly Contract-Manufactured Products) grew 2.0%, though its profitability was hampered by production downtime following a May 2026 cybersecurity incident. Consolidated gross profit margin expanded to 37.7%, benefiting from a favorable product mix and price increases, despite inflationary pressures on plant costs. The company remains active in capital allocation, repurchasing $454.3 million in common stock during the first half of 2026. A significant strategic development includes the July 2026 sale of the SmartDose 3.5mL On-Body Delivery System to AbbVie for approximately $136 million, which is expected to generate a pre-tax gain of $55 million to $60 million in the third quarter. While the company faces ongoing risks related to global trade policies, supply chain volatility, and a pending securities class action, management maintains that current liquidity, supported by a $500 million revolving credit facility, remains sufficient for operational needs. |
| Apr 23, 2026 | mda_quarterly | West Pharmaceutical Services reported strong financial growth for the first quarter of 2026, with consolidated net sales rising 21% to $844.9 million compared to the same period in 2025. Organic net sales grew 15.3%, driven by robust demand for high-value components—specifically Westar®, NovaPure®, and FluroTec® products—and self-injection device platforms. The Proprietary Products segment remains the primary revenue driver, accounting for 82% of total sales, while the West Vantage segment (formerly Contract-Manufactured Products) contributed 18%, bolstered by increased sales of self-injection devices for obesity and diabetes. Operating profit surged 65.5% to $177.1 million, reflecting improved margins and favorable foreign currency translation. The company continues to execute restructuring plans initiated in 2025 to optimize its cost base, which contributed to lower restructuring charges in the current quarter. Capital allocation remains aggressive; the company repurchased $297.6 million in common stock during the quarter under a new $1 billion authorization. While the company faces ongoing litigation regarding a securities class action, it maintains a solid liquidity position with $521.4 million in cash and full access to a $500 million revolving credit facility. Management continues to monitor inflationary pressures on petroleum-based raw materials and potential geopolitical impacts on its global supply chain. |
Source: SEC EDGAR filing text and events; period Jul 23, 2026; filed Jul 23, 2026.
WST company research is available with Aerarium Pro (CAD $10/mo). The five showcase tickers (TSLA, NVDA, AAPL, AMZN, PLTR) and the macro dashboard stay free. Already a subscriber? Sign in to pick up where you left off.